Impax Settles Pending Litigation For Flomax Capsules

Impax Laboratories has reached an agreement with Astellas Pharma and Boehringer Ingelheim to settle pending US litigation with regard to US Patent for Flomax capsules, through the entry of a consent judgment confirming the validity and infringement of the patent.

As a result of this settlement, the case will be terminated by the consent judgment. The settlement of the litigation provides Impax with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity.

The company said that Flomax is a treatment for the functional symptoms of benign prostatic hyperplasia.

The company revealed that according to Wolters Kluwer Health, US sales of Flomax 0.4mg capsules were approximately $1.9 billion for the 12 months ended August 31, 2009.

Impax Laboratories is a technology-based pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division.